Blackrock Neurotech raises $50M Series B to commercialize Utah Array BCI platform
Summary
Salt Lake City-based Blackrock Neurotech secured $50M Series B led by Valor Equity Partners, with Alliance Venture and NEA. The company — whose Utah Array has been used in more human neural recordings than any other device — is using the round to transition from research supplier to commercial BCI company, targeting clinical applications in communication and motor restoration.
Why it matters
Blackrock's 30-year research technology heritage gives them unmatched neural recording credibility. The Valor Equity Partners lead — Peter Thiel's growth fund — signals this round is about commercial scaling, not technology derisking. The Utah Array is the most validated human BCI platform in existence.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial